Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company products are sold in countries around the world. Eli Lilly products include neuroscience, endocrine, anti-infectives, cardiovascular agents, oncology, and animal health products.
Website: lilly.com


  • Bad financial results growth rate -10.5% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (10.0%)
  • Dividend yield for the last twelve months 0.6%
  • Free cash flow yield -0.4% (LTM)
  • Share price is 291.8% higher than minimum and 2.8% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (96.2x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $0.6 mln (-0.000% of cap.)

Key Financials (Download financials)

Ticker: LLY
Share price, USD:  (-0.1%)770
year average price 603.70  


year start price 442.38 2023-05-20

min close price 423.21 2023-05-23

max close price 792.28 2024-03-04

current price 770.00 2024-05-18
Common stocks: 903 782 000

Dividend Yield:  0.6%
FCF Yield LTM: -0.4%
EV / LTM EBITDA: 96.2x
EV / EBITDA annualized: 207.2x
Last revenue growth (y/y):  36.8%
Last growth of EBITDA (y/y):  -57.8%
Historical revenue growth:  12.1%
Historical growth of EBITDA:  7.8%
Target EV / EBITDA (hist percentile):
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 695 912
Net Debt ($m): 17 761
EV (Enterprise Value): 713 673
EBITDA LTM ($m): 7 420
EV / LTM EBITDA: 96.2x
Price to Book: 54.3x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2024-05-17investorplace.com

Pharma Stocks Outlook: Where Are 2024's Top Performers Headed Next?

2024-05-17zacks.com

Eli Lilly's (LLY) Efsitora Matches Daily Insulins in A1C Control

2024-05-17zacks.com

Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

2024-05-16zacks.com

3 Drug Stocks to Watch on Raised 2024 Earnings & Sales Guidance

2024-05-16prnewswire.com

With Once-a-Week Dosing, Insulin Efsitora Alfa Delivers A1C Reduction and Safety Profile Consistent with Daily Insulin

2024-05-14Reuters

Eli Lilly reaches settlement with spa selling Mounjaro, Zepbound knockoffs

2024-05-14The Motley Fool

2 Top Pharma Stocks That Just Keep Getting Better and Better

2024-05-11The Motley Fool

1 No-Brainer Growth Stock to Buy and Hold

2024-05-07Reuters

US FDA panel to discuss Eli Lilly Alzheimer's drug on June 10

2024-05-06The Motley Fool

Why Eli Lilly Stock Jumped by 4% Today
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data